Smiling woman sitting in front of green wall at AlkermesSmiling woman sitting in front of green wall at AlkermesBlue Triangle graphic

News and Events

Sharing Stories of
Patients, Employees
and Communities

Featured News

January 18, 2022

Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Read more

January 06, 2022

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Read more

November 19, 2021

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

Read more

See all press releases

Our Commitment to Responsibility

Corporate responsibility has always played a central role in our business and has proven even more critical during the past year as we faced some of the most pressing public health and societal issues of our time – a dynamic global pandemic, systemic racism in the U.S. and around the world, and a worsening climate change crisis. Guided by our purpose and values, we took actions to respond to these critical issues, while sharpening our focus on scientific and business excellence in our efforts to help people living with complex and difficult-to-treat diseases. Our recently published Corporate Responsibility Report expounds on these efforts.

Corporate Responsibility Reports   

Portrait of woman with mask in research laboratory environment

Alkermes Gives Back

Alkermes employees seek to make a positive impact in their communities by taking part in Alkermes in Action, our employee-led volunteer program that represents our commitment to giving back to our local communities.  

Learn more

Cancer Trials At-a-Glance

Learn more about our ongoing clinical research program for nemvaleukin alfa, our lead immuno-oncology candidate. The investigational IL-2 variant immunotherapy is currently being studied across clinical trials evaluating intravenous and subcutaneous dosing. 

View infographic

Portrait of smiling Alkermes employee smiling

Blair Jackson in Alkermes office smiling.

Unlocking IL-2's Potential

As the unmet medical need in oncology changes, Alkermes is using its R&D capabilities honed over 30 years of work on complex diseases to investigate a potential next breakthrough in cancer therapy. 

Read the Scrip article

Media Resources

Company Description

Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.

Media Inquiries

Email our media team

Company Logos


Company Photo


Corporate Fact Sheet


Follow us on our social channels   

blue triangle graphic

Statements and Positions

The idea that a corporation can play a profoundly positive role in society is central to our vision. It is our obligation to voice our beliefs about issues that impact the patients we serve, the communities in which we live and work and society at large.

Company Response to Board Nominations

Read our statement

Marketing Practices

Read our statement

Systemic Racism and Violence

Read our statement

Company Response to COVID-19

Read our response